"Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victory" was originally created and published by Clinical Trials ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer ...

Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...

Inhibrx Biosciences shares surged nearly 76% in after-hours trading Thursday after the company reported positive Phase 2 ...

Inhibrx Biosciences shares jumped in premarket trading after the company reported positive trial results for its cancer drug ozekibart, including promising data from expanded use. Shares jumped 62% to ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced ...

Chondrosarcoma is a group of bone cancers that start in the cartilage. Cartilage is a connective tissue found in many parts of your body, such as in your joints where your bones meet. About 1 in ...

Most people who have cancer cells in their bones don't have primary bone cancer. They have cancer cells that have spread into the bone from a cancer elsewhere in the body. This is called secondary or ...

Chondrosarcoma is a type of bone cancer that forms in the cells of cartilage. Symptoms can vary but may include swelling and pain in the area of the tumor. Surgery is usually the first treatment for ...